ArticleInfection and immunity2004
Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
Article in Infection and immunity, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 58 citations in OpenAlex.
- Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality.The Journal of infectious diseases · 2007Trial
- Mannoprotein Cig1 contributes to the immunogenicity of a heat-killed F-box protein Fbp1Infection and immunity · 2026Article
- Will the Real Immunogens Please Stand Up: Exploiting the Immunogenic Potential of Cryptococcal Cell Antigens in Fungal Vaccine Development.Journal of fungi (Basel, Switzerland) · 2024Review
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- Antibody Isolation in C. neoformans.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Monoclonal Antibodies against Cell Wall Chitooligomers as Accessory Tools for the Control of Cryptococcosis.Antimicrobial agents and chemotherapy · 2021Article
- Article
- Monoclonal Antibodies as Tools to Combat Fungal Infections.Journal of fungi (Basel, Switzerland) · 2020Review
- Immunoglobulin M in Health and Diseases: How Far Have We Come and What Next?Frontiers in immunology · 2020Review
- Host immunity to Cryptococcus neoformans.Future microbiology · 2015Review
- X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection.mBio · 2013Article
- Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms.The American journal of pathology · 2012Article
- IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Antibodies to Streptococcus pneumoniae capsular polysaccharide enhance pneumococcal quorum sensing.mBio · 2011Article
- Characterization of gene use and efficacy of mouse monoclonal antibodies to Streptococcus pneumoniae serotype 8.Clinical and vaccine immunology : CVI · 2011Article
- TLR9 signaling is required for generation of the adaptive immune protection in Cryptococcus neoformans-infected lungs.The American journal of pathology · 2010Article
- The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Improved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformans.Infection and immunity · 2010Article
- The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.Vaccine · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The features of protective murine antibodies to the Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) have been rigorously investigated; however, the characteristics of protective human antibodies to GXM have not been defined. We produced monoclonal antibodies (MAbs) from XenoMouse mice (transgenic mice that express human immunoglobulin M [IgM], IgG2, and kappa) which were immunized with a C. neoformans serotype D strain 24067 GXM-diphtheria toxoid conjugate. This study reports the specificity and efficacy of three human IgM MAbs, G14, G15, and G19, generated from these mice. Each MAb was specific for GXM, but G14 and G19 had different specificity based on their binding to serotype A strain H99 and SB4 GXMs, to which G15 did not bind. Nucleic acid sequence analysis revealed that G15 uses V(H)3-64 in the germ line configuration. G14 and G19 use V(H)6-1, which has somatic mutations. All of the MAbs use V kappa DPK22/A27. Studies of MAb efficacy in BALB/c mice showed that administration of 0.1 mg, but not 1 or 0.01 mg, of G15 prolonged survival against lethal C. neoformans strain 24067 challenge, whereas G14 and G19 were not protective at any dose. This panel of MAbs illustrates that serotype D GXM has epitopes that elicit human antibodies that can be either protective or nonprotective. Our findings suggest that V(H) gene use may influence GXM specificity and efficacy, and they provide insights into the possible contribution that V(H) gene use may have in resistance and susceptibility to cryptococcosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.